Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,470.00
(
-1.06%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,490.99
(
-0.04%
)
News Focus
News Focus
Post# of 257265
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 170131

Monday, 11/18/2013 3:18:29 PM

Monday, November 18, 2013 3:18:29 PM

Post# of 257265
ABBV/ENTA—Agree with your comments vis-à-vis cirrhotic patients and the importance of the TURQUOISE-2 study to the overall commercial uptake of the regimen.

However, I don’t fully understand why you think the non-ribavirin arms of PEARL-2/3/4 are so easy to handicap. For the record, what are your expectations for each of these trial arms? T.i.a.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today